Barbados is taking a major step toward reshaping its national healthcare framework, as a transformative new piece of legislation targeting pharmaceutical regulation and supply chain security moves forward through the country’s Parliament. Titled the Barbados Medical Products Bill, the proposed law marks a historic milestone not just for its policy goals, but also for the procedural context in which it was introduced: it was piloted through its second reading in the House of Assembly by Health Minister Senator Lisa Cummins, marking the first time a sitting senator has appeared on the floor of the lower house of parliament following constitutional amendments ratified late last year.
In her address to lawmakers, Minister Cummins framed the bill as a critical step toward establishing full medical products sovereignty for the Caribbean island, with public safety serving as the core priority. The primary risk the new regulations aim to address is the growing threat of counterfeit pharmaceuticals, which put public health at severe risk through untested ingredients and fraudulent claims of efficacy. Key to the new regulatory structure is Section 6 of the bill, which lays out formal requirements for the registration and marketing authorization of all medical products sold or distributed in Barbados.
Minister Cummins emphasized that strong, centralized regulation is non-negotiable to protect Barbadians from substandard or fraudulent drugs that are often marketed with false claims about their ability to treat medical conditions. “One of the things that this legislation is meant to do is to protect this community by way of regulation from counterfeiting drugs and drugs that are marketed to do one thing but really are not doing what they’re said to do,” she told assembled lawmakers.
The push for this new framework grew directly out of disruptions that hit the island during the COVID-19 pandemic, when global supply chain breakdowns and export restrictions left many small nations struggling to access critical medical supplies. Compounding those ongoing challenges are current global supply chain disruptions linked to rising international tensions, which have added new layers of uncertainty to global pharmaceutical trade. Currently, Barbados imports 47 percent of all pharmaceutical products consumed domestically, a level of dependence that left the country extremely vulnerable during recent crises.
Minister Cummins described the confluence of pandemic-related disruptions, export bans, international supply chain breakdowns, and country-level hoarding of medical supplies as a “perfect storm” – but also a perfect opportunity to build long-term self-reliance. The bill aligns with Barbados’ broader national strategy to secure sovereignty across key strategic sectors, from energy and agriculture to food production, now extending that momentum to health and medical supplies. The goal, she stressed, is to ensure Barbados is never again fully reliant on the goodwill of foreign nations, a vulnerability laid bare during the peak of the COVID-19 pandemic when many countries prioritized domestic access to critical supplies over exports.
A core complementary initiative tied to the bill is the launch of Barbados Pharmaceutical Inc., a state-backed domestic pharmaceutical production company that will serve as a foundation to transform Barbados from a regional logistics hub into a full-fledged pharmaceutical, distribution, and regulatory hub for the Caribbean and broader global south. Minister Cummins revealed that the new facility is already working with key partners in Nigeria to build collaborative partnerships with pharmaceutical manufacturers across the African continent, opening new avenues for South-South cooperation in pharmaceutical production.
The bill also formalizes the structure for a new Barbados Medical Products Regulatory Authority, which will operate under the legislation’s framework to oversee both domestic manufacturing and research and development activity carried out at the Barbados Living Lab, the country’s new pharmaceutical R&D facility. Minister Cummins simplified the authority’s role: just as the U.S. Food and Drug Administration provides trusted verification of pharmaceutical safety and efficacy for global markets, the new Barbadian regulator will fill that same role for domestic and regional production. Without a formal, robust regulatory framework, she noted, domestic manufacturing and international collaboration cannot expand.
The legislation also draws heavily on existing regional regulatory frameworks across both the Caribbean and African regions, where leaders have prioritized expanding domestic pharmaceutical manufacturing and strengthening independent regulatory authorities. Under the new structure, the existing Barbados Drug Service will be separated from the new regulatory authority, which will take on full independent oversight of all medical products. The bill also incorporates formal requirements for pharmacovigilance, including systematic quality monitoring, processes for product recalls, and removal of unsafe products from the market.
From the moment pharmaceutical products arrive at Barbados’ border, through customs clearance, import licensing, and final placement on retail shelves, multiple government agencies including Customs, the Department of Commerce, the new regulatory authority, and the Ministry of Health will collaborate to maintain extensive regulatory oversight and surveillance, with each institution holding clear defined responsibilities under the law.
The procedural milestone of a senator presenting legislation to the House of Assembly follows the December 2023 ratification of amendments to the Constitution of Barbados, which explicitly allow sitting ministers from the Senate to attend sittings of the House of Assembly, and vice versa for ministers sitting in the lower house. The first cross-chamber ministerial appearance took place just last week, when two members of the House of Assembly – Criminal Justice Minister Michael Lashley and Attorney General Wilfred Abrahams – presented the Criminal Gangs (Prevention and Control) Bill for its second reading before the Senate.